Disclaimer for Endo Pharmaceuticals

Conditions for Use of Endo's Websites

Please read these terms of use carefully. If you proceed to use this site, you are agreeing to abide by these rules. This website is meant as an introduction to the activities of Endo Pharmaceuticals Holdings Inc. and its subsidiaries ("Endo").

Noncommercial Use

This site is produced by Endo. Endo gives you permission to copy documents published by Endo on the World Wide Web for noncommercial use only, provided any copy of these documents that you make shall retain all copyright and other proprietary notices contained herein. Unauthorized reproduction of Endo's websites and the material and/or information elements that comprise them is strictly prohibited.

Copyrights

All images and text are owned by or licensed to Endo and may not be downloaded, distributed, stored, reused, reposted, modified, or otherwise used except as provided herein without the express written permission of Endo.

Trademarks

All product and service names appearing in a typeface different from that of the surrounding text or with a trademark symbol, including the Endo logo, are trademarks and/or service marks owned by or licensed to Endo, its subsidiaries or its affiliates. Use of these marks, except as permitted herein, is expressly prohibited.

License

Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Endo or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Endo copyright or other proprietary right.

Scope of Information

The site contains information about products that may or may not be available in any particular country or region of the world, may be available under different trademarks in different countries and, where applicable, may be approved or cleared by a government regulatory body for sale or use with different indications and restrictions in different countries.

Although accessible by others, the U.S. product information on Endo and Endo websites is intended for use by US residents only. You should not construe anything on the site as a promotion or solicitation for any product or for the use of any product outside the United States.

Disclaimer

Endo offers the information on this website for general educational and informational purposes only. This information should not be considered as a replacement for consultation with Endo representatives. Endo 's US Customer Support Center can be reached by calling the following number (in the US): 1-800-462-ENDO (3636). While Endo has endeavored to make sure that the information contained in this website is accurate, Endo cannot guarantee the accuracy of such information, and it is provided AS IS without warranty or guarantee of any kind, either expressed or implied, including, but not limited to, implied warranty of merchantability, fitness for a particular purpose and/or noninfringement. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

The information contained in this site is not meant to substitute for medical care or treatment. Nothing takes the place of speaking with your doctor or other healthcare professional. PLEASE CONSULT WITH YOUR DOCTOR OR OTHER HEALTH CARE PROFESSIONAL BEFORE USING ANY DRUG PRODUCT DISCUSSED WITHIN THIS WEBSITE.

Information sent to Endo

Should any viewer of an Endo-published document respond with information (including feedback, data, graphics, questions, comments, suggestions, or the like) regarding the content of such Endo document, that information shall be deemed to be nonconfidential and Endo shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. Endo shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever, including, but not limited to, developing, manufacturing, and marketing products incorporating such information. Endo actively enforces its intellectual property rights to the fullest extent of the law.

Links to Other Websites

As a useful resource to our visitors, Endo provides links to other websites. We try to carefully choose websites that we believe are useful and of high quality. However, because websites can change very quickly, we cannot guarantee, and do not monitor, the content of any website to which we provide a link or reference. In addition, Endo shall assume no liability for the content of non- Endo sites. Further, Endo shall not bear any liability for alleged or actual damages or injury arising from a user's access to such sites. Links to other sites are provided only as a convenience to users of our site.

Concerning Your Privacy

Endo is committed to respecting the privacy of its website visitors. We recognize the need to balance legitimate business interests in collecting and using information received from and about you with your reasonable expectations of privacy. Below is a description of how we use information learned about you from your visit to our website.

Aggregate Data

Endo's website may deposit certain bits of information called "cookies" in a visitor's computer. Cookies can tell us how and when pages in a website are visited and by how many people. This technology does not collect an individual visitor's identifying information. Rather, this information is in an aggregate form. The purpose of this technology and the information it provides is to help us to improve our websites.

Personally Identifiable Information

Endo collects personally identifiable information, such as names, addresses, email addresses and the like, only when voluntarily provided by a website visitor. We will notify you as to the uses we intend to make of that information in any given instance. Personally identifiable information will not be sold, rented or exchanged with any other organization or entity unless the user is first notified and expressly agrees to it.

Where visitors choose to provide the site with a name, email address or other information in order to receive email notices of new postings or other materials that may be offered, Endo keeps all such response lists confidential.

Children

We do not collect personally identifiable information about children.

Changes

Any changes to this privacy policy will be communicated promptly on this page.

Forward-Looking Statements

We have made forward-looking statements on this website within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates and projections. Statements that are not historical facts, including statements which are preceded by, followed by, or that include, the words "believes", "anticipates", "plans", "expects" or similar expressions and statements are forward-looking statements. Endo's estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect Endo's current perspective on existing trends and information. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements made on this website. Important factors that may affect future results include, but are not limited to: market acceptance of the Company's products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company's product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and regulations; customer demand; possible future litigation; availability of future financing and reimbursement policies of government and private health insurers and others; and other risks and uncertainties detailed in Endo's filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 filed with the SEC on April 30, 2004, as amended. Readers should evaluate any statement in light of these important factors.

We do not undertake any obligation to update our forward-looking statements after the date of our website launch for any reason, even if new information becomes available or other events occur in the future.

Important Safety Information

OPANA® ER has a boxed warning as follows:

WARNING: OPANA ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OPANA ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OPANA ER is an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

OPANA ER is NOT intended for use as an as needed analgesic.

OPANA ER TABLETS are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed OPANA ER TABLETS leads to rapid release and absorption of a potentially fatal dose of oxymorphone.

Patients must not consume alcoholic beverages, or prescription or nonprescription medications containing alcohol, while on OPANA ER therapy. The co-ingestion of alcohol with OPANA ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

OPANA, like OPANA ER, contains oxymorphone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to morphine and can be abused in a manner similar to other opioid agonists, legal or illicit.

OPANA and OPANA ER are contraindicated in patients with a known hypersensitivity to oxymorphone hydrochloride, morphine analogs such as codeine, or any of the other ingredients of OPANA and OPANA ER; in patients with moderate or severe hepatic impairment or in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), acute or severe bronchial asthma, hypercarbia, and in any patient who has or is suspected of having paralytic ileus.

OPANA ER is not indicated for pain in the immediate post-operative period (the first 12–24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate (see American Pain Society guidelines).

Respiratory depression is the chief hazard of OPANA and OPANA ER, particularly in elderly or debilitated patients. OPANA and OPANA ER should be administered with extreme caution to patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma.

Patients receiving other opioid analgesics, general anesthetics, phenothiazines or other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) may experience additive effects resulting in respiratory depression, hypotension, profound sedation, or coma.

OPANA and OPANA ER should be used with caution in elderly and debilitated patients and in patients who are known to be sensitive to CNS depressants, such as those with cardiovascular, pulmonary, renal, or hepatic disease. OPANA and OPANA ER should be used with caution in patients with mild hepatic impairment and in patients with moderate to severe renal impairment. These patients should be started cautiously with lower doses of OPANA or OPANA ER while carefully monitoring for side effects.

OPANA ER is not indicated for preemptive analgesia (administration preoperatively for the management of postoperative pain).

The most common adverse drug reactions (≥10%) reported at least once by patients treated with OPANA in the clinical trials were nausea and pyrexia. The most common adverse drug reactions (≥10%) in clinical trials for OPANA ER were nausea, constipation, dizziness (excluding vertigo), vomiting, pruritus, somnolence, headache, increased sweating, and sedation.

Patients and their families should be instructed to flush any OPANA and OPANA ER tablets that are no longer needed.

Please see full Prescribing Information for OPANA and full Prescribing Information, including boxed WARNING for OPANA ER.

Vermont prescribers, please see additional information for OPANA and OPANA ER.

Oxymorphone is also available in injectable form. For more information, please see the full prescribing information for OPANA Injection.